Quarterly report pursuant to Section 13 or 15(d)

Note 3 - Revenue From Contracts With Customers (Tables)

v3.21.1
Note 3 - Revenue From Contracts With Customers (Tables)
3 Months Ended
Mar. 31, 2021
Notes Tables  
Disaggregation of Revenue [Table Text Block]
   
Three Months Ended
March 31,
 
   
2021
   
2020
 
Royalty revenue:
               
Tc99m tilmanocept - Europe
  $
    $
15,221
 
                 
License revenue:
               
Tc99m tilmanocept - Europe
  $
22,486
    $
 
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]
   
Three Months Ended March 31,
 
   
2021
   
2020
 
Total deferred revenue, beginning of period
  $
700,000
    $
700,000
 
Revenue recognized from satisfaction of performance obligations
   
     
 
Total deferred revenue, end of period
  $
700,000
    $
700,000